Abstract

Tumor necrosis factor-α (TNFα) activates both cell death and cell survival pathways. The activation of survival pathway renders most cancer cells resistant to TNF-induced cytotoxicity. We found that pretreatment with digitoflavone, a plant flavonoid, greatly sensitized TNFα-induced apoptotic cell death in several human pancreatic cancer cells. In search of the molecular basis of the sensitization effect of digitoflavone, digitoflavone was found to inhibit TNFα-induced activation of nuclear transcription factor-kappa B (NF-κB) which is the main survival factor in TNFα signaling. NF-κB suppression occurred through inhibition of IκBα kinase activation, IκBα phosphorylation, IκBα degradation, and NF-κB nuclear translocation. This inhibition correlated with suppression of NF-κB-dependent genes involved in antiapoptosis (mcl-1, bcl-2, bcl-xl, c-iap1, c-iap2, flip, and survivin), proliferation (c-myc, cyclin d1), and angiogenesis (vegf, cox-2, and mmp-9). In addition, digitoflavone can activate JNK through inhibition of NF-κB signaling, provide a continuous blockade of the feed-back inhibitory mechanism by JNK-induced NF-κB activation. This study found a novel function of digitoflavone and enhanced the value of digitoflavone as an anticancer agent.

Highlights

  • Pancreatic cancer is the fourth leading cause of death in cancer patients in the U.S and is a global cancer treatment problem [1]

  • Nuclear factor-kB (NF-kB) is constitutively activated in primary pancreatic adenocarcinoma and pancreatic cancer cell lines [8], and downregulated NF-kB forms the biological rationale for effective management of patients with pancreatic carcinoma by using a nontoxic phytochemical [11]

  • Tumor necrosis factor-a (TNFa) by itself did not induce a significant amount of apoptosis; when combined with digitoflavone, the cytotoxic effects of TNFa were enhanced (Fig. 1)

Read more

Summary

Introduction

Pancreatic cancer is the fourth leading cause of death in cancer patients in the U.S and is a global cancer treatment problem [1]. Traditional treatment modalities for unresectable pancreatic cancer include radiation alone, chemotherapy alone, or combined chemoradiation. The principal drug currently used in the treatment of patients who have pancreatic cancer is gemcitabine, which has an objective response rate of only 5% [4]. Chemoresistance of tumor cells is apparently the major cause of failure of conventional chemotherapy in the treatment of pancreatic cancer. More than 90% of pancreatic cancer cells harbor mutated K-ras [7], and NF-kB is a downstream effector of this oncogenic Ras [8,9,10]. The development of compounds that target NF-kB is proposed as an approach for the treatment of patients with pancreatic cancer [6,14,15]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call